Adjuvant Metronomic Chemotherapy After Surgery in pT1-T2 N0 M0 HER2-Positive and ER/PR-Positive Breast Cancer Plus Targeted Therapy, Anti-Hormonal Therapy, and Radiotherapy, with or Without Immunotherapy: A New Operational Proposal.

Roncati L

Open source

DOI
10.3390/cancers17081323
Published
2025 Apr 15
Container
Cancers
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/cancers17081323,
  title = {Adjuvant Metronomic Chemotherapy After Surgery in pT1-T2 N0 M0 HER2-Positive and ER/PR-Positive Breast Cancer Plus Targeted Therapy, Anti-Hormonal Therapy, and Radiotherapy, with or Without Immunotherapy: A New Operational Proposal.},
  author = {Roncati L},
  year = {2025},
  journal = {Cancers},
  doi = {10.3390/cancers17081323},
  url = {https://doi.org/10.3390/cancers17081323}
}

RIS

TY  - JOUR
TI  - Adjuvant Metronomic Chemotherapy After Surgery in pT1-T2 N0 M0 HER2-Positive and ER/PR-Positive Breast Cancer Plus Targeted Therapy, Anti-Hormonal Therapy, and Radiotherapy, with or Without Immunotherapy: A New Operational Proposal.
AU  - Roncati L
PY  - 2025
JO  - Cancers
DO  - 10.3390/cancers17081323
UR  - https://doi.org/10.3390/cancers17081323
ER  - 

APA

L, R. (2025). Adjuvant Metronomic Chemotherapy After Surgery in pT1-T2 N0 M0 HER2-Positive and ER/PR-Positive Breast Cancer Plus Targeted Therapy, Anti-Hormonal Therapy, and Radiotherapy, with or Without Immunotherapy: A New Operational Proposal.. Cancers. https://doi.org/10.3390/cancers17081323

Source records